CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series

Stephanie Ruf; Holger Hebart; Lisa Lyngsie Hjalgrim; Edita Kabickova; Peter Lang; Daniel Steinbach; Georg C Schwabe; Wilhelm Woessmann

doi:10.1002/pbc.27003

CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series

Stephanie Ruf, Holger Hebart, Lisa Lyngsie Hjalgrim, Edita Kabickova, Peter Lang, Daniel Steinbach, Georg C Schwabe, Wilhelm Woessmann

21 Citations (Scopus)

Abstract

Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.

Original language	English
Journal	Pediatric Blood & Cancer
Volume	65
Issue number	6
Pages (from-to)	e27003
ISSN	1545-5009
DOIs	https://doi.org/10.1002/pbc.27003
Publication status	Published - Jun 2018
Externally published	Yes

Keywords

Adolescent
Adult
Anaplastic Lymphoma Kinase/metabolism
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Central Nervous System Diseases/chemically induced
Child
Child, Preschool
Disease Progression
Female
Humans
Lymphoma, Large-Cell, Anaplastic/drug therapy
Male
Molecular Targeted Therapy/adverse effects
Neoplasm Recurrence, Local/drug therapy
Prognosis
Survival Rate
Vinblastine/adverse effects
Young Adult

Access to Document

10.1002/pbc.27003

Cite this

@article{24ed9934bea540b19b0a6c14931c4a00,

title = "CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series",

abstract = "Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.",

keywords = "Adolescent, Adult, Anaplastic Lymphoma Kinase/metabolism, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Central Nervous System Diseases/chemically induced, Child, Child, Preschool, Disease Progression, Female, Humans, Lymphoma, Large-Cell, Anaplastic/drug therapy, Male, Molecular Targeted Therapy/adverse effects, Neoplasm Recurrence, Local/drug therapy, Prognosis, Survival Rate, Vinblastine/adverse effects, Young Adult",

author = "Stephanie Ruf and Holger Hebart and Hjalgrim, \{Lisa Lyngsie\} and Edita Kabickova and Peter Lang and Daniel Steinbach and Schwabe, \{Georg C\} and Wilhelm Woessmann",

note = "{\textcopyright} 2018 Wiley Periodicals, Inc.",

year = "2018",

month = jun,

doi = "10.1002/pbc.27003",

language = "English",

volume = "65",

pages = "e27003",

journal = "Pediatric Blood \& Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma

T2 - A case series

AU - Ruf, Stephanie

AU - Hebart, Holger

AU - Hjalgrim, Lisa Lyngsie

AU - Kabickova, Edita

AU - Lang, Peter

AU - Steinbach, Daniel

AU - Schwabe, Georg C

AU - Woessmann, Wilhelm

PY - 2018/6

Y1 - 2018/6

N2 - Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.

AB - Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration.

KW - Adolescent

KW - Adult

KW - Anaplastic Lymphoma Kinase/metabolism

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

KW - Central Nervous System Diseases/chemically induced

KW - Child

KW - Child, Preschool

KW - Disease Progression

KW - Female

KW - Humans

KW - Lymphoma, Large-Cell, Anaplastic/drug therapy

KW - Male

KW - Molecular Targeted Therapy/adverse effects

KW - Neoplasm Recurrence, Local/drug therapy

KW - Prognosis

KW - Survival Rate

KW - Vinblastine/adverse effects

KW - Young Adult

UR - https://www.scopus.com/pages/publications/85043332120

U2 - 10.1002/pbc.27003

DO - 10.1002/pbc.27003

M3 - Journal article

C2 - 29512859

SN - 1545-5009

VL - 65

SP - e27003

JO - Pediatric Blood & Cancer

JF - Pediatric Blood & Cancer

IS - 6

ER -

CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this